Emily Whitehead, who was successfully treated for leukemia at the age of 7 through CAR T-cell therapy, recently visited Fargo to meet with researchers who played a key role in developing the life-saving treatment.
It is a rare opportunity for cancer researchers to interact with a patient who has been cured and is alive today due to the groundbreaking work that originated in laboratories, including those in Fargo. Emily Whitehead, the first child in the world to undergo CAR T-cell therapy to combat cancer, now serves as an advocate for research and treatments on a global scale.
During a tour of Aldevron in Fargo, Emily and her father, Tom, were able to witness the early stages of the research process. They visited various labs and high-tech rooms where Aldevron conducts its research, with one researcher explaining, “My job is to manipulate the growth curve.”
At just 5 years old, Emily Whitehead was diagnosed with lymphoblastic leukemia, and after conventional treatments proved ineffective, she was enrolled in an experimental CAR T-cell therapy trial. This innovative treatment ultimately led to her being the first pediatric patient in the world to be cured of leukemia using CAR T-cell therapy.
CAR T-cell therapy involves modifying a patient’s immune cells to target and destroy cancer cells. Aldevron in Fargo played a crucial role in manufacturing the necessary materials for researchers, including those involved in Emily’s groundbreaking treatment.
The impact of Emily’s story has been profound, not only for her family but also for the researchers and medical professionals involved in her treatment. Tom Whitehead expressed gratitude towards Aldevron, acknowledging that their work in 2012 was instrumental in saving Emily’s life. The Whitehead family continues to be actively involved in supporting more treatments for pediatric cancer patients through the Emily Whitehead Foundation.
Emily’s visit to the labs in Fargo provided a tangible reminder of the significance of research and the individuals behind the process. She emphasized the importance of recognizing the contributions of researchers, stating that their work, no matter how small it may seem, has a significant impact on children battling cancer.
Thirteen years after her treatment, Emily remains cancer-free at the age of 20 and is preparing to attend college. She is committed to continuing her advocacy work through the Emily Whitehead Foundation, ensuring that children worldwide have access to life-saving treatments similar to the one that saved her life.
Key Takeaways:
– Emily Whitehead, the first pediatric patient to be cured of leukemia using CAR T-cell therapy, visited Fargo to meet with researchers who played a pivotal role in her treatment.
– Aldevron in Fargo was involved in manufacturing materials for CAR T-cell therapy, contributing to the success of Emily’s treatment.
– Emily’s story serves as a powerful reminder of the impact of research and the importance of supporting treatments for pediatric cancer patients.
– The Emily Whitehead Foundation, founded by Emily and her family, continues to advocate for increased access to life-saving treatments for children battling cancer.
Read more on inforum.com